Biogen Signs Preclinical Gene Editing Deal with Sangamo
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 3 (Table of Contents)
Published: 4 Mar-2020
DOI: 10.3833/pdr.v2020.i3.2516 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Continuing to bolster its early-stage pipeline, Biogen has partnered with Sangamo Therapeutics to develop gene editing treatments for neurology indications using the latter’s zinc finger nuclease technology...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS